Financial Performance - The company's operating revenue for 2024 reached ¥1,819,075,569.77, representing a 35.64% increase compared to ¥1,341,074,347.86 in 2023[16]. - The net profit attributable to shareholders for 2024 was ¥220,261,152.36, up 31.05% from ¥168,069,329.73 in 2023[16]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥162,128,382.52, a 39.58% increase from ¥116,155,426.61 in 2023[16]. - The net cash flow from operating activities for 2024 was ¥320,130,370.41, showing a significant increase of 103.99% compared to ¥156,936,759.28 in 2023[16]. - The basic earnings per share for 2024 was ¥1.7729, reflecting a 31.65% increase from ¥1.3467 in 2023[16]. - Total assets at the end of 2024 amounted to ¥3,918,827,588.40, a 6.03% increase from ¥3,695,914,140.16 at the end of 2023[16]. - The net assets attributable to shareholders at the end of 2024 were ¥3,119,631,283.07, up 1.19% from ¥3,082,975,745.74 at the end of 2023[16]. - The company reported a total revenue of 58,132,769.84, an increase from 51,913,903.12 in the previous period, reflecting a growth of approximately 23.5%[22]. - The revenue from the mold and injection industry was ¥1,204,648,145.77, accounting for 66.23% of total revenue, with a year-on-year growth of 27.05%[60]. - The health appliance sector generated ¥537,777,972.42, which is 29.56% of total revenue, showing a significant increase of 42.83% from the previous year[60]. - The overseas revenue accounted for 43.23% of total revenue, increasing by 44.64% from the previous year[60]. Dividend Distribution - The company plans to distribute a cash dividend of 6 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The board of directors has approved the profit distribution plan based on the total number of shares minus those in the repurchase account[3]. - The profit distribution plan for 2024 includes cash dividends of RMB 6 per 10 shares, with no stock dividends or capital reserve transfers[179]. - The total cash dividend amount for the current year is RMB 74,880,000, representing 100% of the profit distribution total[178]. - For the first half of 2024, the company intends to distribute cash dividends of RMB 5 per 10 shares, amounting to RMB 62,185,814.50[175]. Strategic Acquisitions and Market Position - The company completed the acquisition of Yuke Plastic (Xiamen) Co., Ltd. in May 2024, positioning itself as a primary supplier for leading domestic new energy manufacturers[31]. - The company has established a global production base with facilities in Xiamen, Shanghai, Tianjin, Quanzhou, Germany, Malaysia, Mexico, and Vietnam, enhancing its market reach[26]. - The company has established long-term partnerships with major clients across various sectors, including automotive, outdoor home, electronics/robotics, and health appliances, enhancing its market presence[55]. - The company has established subsidiaries in the United States and Singapore as part of its marketing network expansion[102]. - The company has established subsidiaries in Germany, Malaysia, Mexico, Singapore, the United States, and Vietnam to expand overseas markets, facing potential operational risks due to differing legal and cultural environments[119]. Research and Development - The company has invested significantly in R&D, with a total of 501 authorized patents, including 31 invention patents, enhancing its long-term competitive advantage[50]. - The company is focusing on the development of ultra-precision injection molds, aiming to enhance production efficiency and reduce costs through innovative temperature control methods[74]. - Research is being conducted on high-gloss, spray-free injection molding technology to improve surface quality and mold lifespan, addressing key technical bottlenecks[74]. - The company is implementing a new design for a shaft insert positioning mechanism to ensure accurate alignment and reduce defect rates during production[74]. - R&D investment amounted to ¥86,286,432.38 in 2024, an increase of 24.63% from ¥69,251,198.07 in 2023[76]. - The number of R&D personnel increased by 23.26% to 408 in 2024 from 331 in 2023[75]. Operational Efficiency and Management - The company has implemented advanced manufacturing equipment and MES systems to enhance production efficiency and flexibility[52]. - The company has developed an information management system that integrates resources across procurement, production, sales, and R&D, improving operational efficiency[58]. - The company has established a comprehensive production line for precision injection molds, injection parts, and health products, creating a synergistic effect across the supply chain[43]. - The production of injection parts follows a "sales-driven production" model, aligning production plans with sales orders and inventory levels[47]. - The company has a complete procurement, R&D, production, and sales system, ensuring its ability to operate independently in the market[136]. Governance and Compliance - The company has held two shareholder meetings during the reporting period, ensuring compliance with legal procedures and facilitating participation from minority shareholders[125]. - The governance structure of the company has improved, ensuring independence from the controlling shareholder and maintaining operational autonomy[126]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholders[131]. - The company has established specialized committees under the board to enhance governance and promote sustainable development[127]. - The board of directors has been diligent in their responsibilities, ensuring compliance with relevant laws and regulations throughout the reporting period[165]. Employee Management and Compensation - The total number of employees at the end of the reporting period is 3,566, with 2,594 in production, 134 in sales, 408 in technology, 84 in finance, and 346 in administration[171]. - The company has established a competitive compensation system to enhance employee motivation and align with business growth[172]. - The company has implemented a comprehensive training program to foster talent development and enhance employee skills[173]. - The company has established a performance evaluation mechanism for senior management, linking their compensation to annual performance targets and overall company performance[189]. Risks and Challenges - The company faces risks from fluctuating international trade tariffs, which have impacted operations, and will diversify its business to reduce dependence on single markets[117]. - The overall gross margin has slightly declined compared to the previous year due to rising labor costs and raw material price fluctuations, prompting the company to enhance product quality and innovation efforts[118]. - The company is addressing management challenges arising from rapid expansion by strengthening human resource management and recruiting high-skilled talent[120].
唯科科技(301196) - 2024 Q4 - 年度财报